Top Line: While common sense informs us stereotactic radiosurgery (SRS) for multiple brain metastases achieves the best quality of life for all but the most rapidly progressive disease, it’s always nice to have a clinical trial to point to.
The Study: Today we bring you an actual prospective randomized trial where 196 patients with 5-20 brain mets received SRS versus hippocampal-avoidance whole brain radiation (HA-WBRT) + memantine. The primary endpoint was 6-month change in symptom burden, as measured using the MD Anderson Symptom Inventory–Brain Tumor instrument (scale 0-10 where 0 is no symptoms). SRS slightly improved symptoms (mean change −0.32), while HA-WBRT slightly worsened them (+0.74), yielding a clinically meaningful −1.06 difference (P<.001). Median overall survival was similar at just over 8 months. As expected, there were more new distant brain mets at 1 year after SRS (45%) than HA-WBRT (24%), but dramatically lower local recurrence (0.8% versus 12.3%). SRS also achieved better functional independence and performance status over time. Neurocognitive testing favored SRS across multiple domains at 12 months, while HA-WBRT had lower rates of radiation necrosis. Commonsense prevails.
TBL: We currently have two sophisticated, safe and effective radiotherapy options for multiple brain metastasis, with SRS favoring neurocognition and local control–ideal for most patients who readily sign-up for short-interval MRI surveillance–and HA-WBRT favoring distant brain control–ideal for extremely rapid intracranial disease progression and/or patients who will not or cannot present for short-interval follow-up. | Aizer, JAMA 2026
The Study: Today we bring you an actual prospective randomized trial where 196 patients with 5-20 brain mets received SRS versus hippocampal-avoidance whole brain radiation (HA-WBRT) + memantine. The primary endpoint was 6-month change in symptom burden, as measured using the MD Anderson Symptom Inventory–Brain Tumor instrument (scale 0-10 where 0 is no symptoms). SRS slightly improved symptoms (mean change −0.32), while HA-WBRT slightly worsened them (+0.74), yielding a clinically meaningful −1.06 difference (P<.001). Median overall survival was similar at just over 8 months. As expected, there were more new distant brain mets at 1 year after SRS (45%) than HA-WBRT (24%), but dramatically lower local recurrence (0.8% versus 12.3%). SRS also achieved better functional independence and performance status over time. Neurocognitive testing favored SRS across multiple domains at 12 months, while HA-WBRT had lower rates of radiation necrosis. Commonsense prevails.
TBL: We currently have two sophisticated, safe and effective radiotherapy options for multiple brain metastasis, with SRS favoring neurocognition and local control–ideal for most patients who readily sign-up for short-interval MRI surveillance–and HA-WBRT favoring distant brain control–ideal for extremely rapid intracranial disease progression and/or patients who will not or cannot present for short-interval follow-up. | Aizer, JAMA 2026